Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic...

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are approved for breast cancer treatment, inducing G1 cell cycle arrest.
• Oncolytic viruses, such as adenoviruses, promote S-phase progression for replication and cancer cell lysis.
• Both therapeutic strategies target the Retinoblastoma protein (Rb) but through distinct mechanisms.

Purpose of the Study:

• To investigate the combined efficacy of CDK4/6 inhibitors and oncolytic adenovirus XVir-N-31.
• To elucidate the molecular mechanisms underlying the potentiation of anti-tumor effects.

Main Methods:

• Treatment of bladder cancer and murine Ewing sarcoma xenograft models with CDK4/6 inhibitors and XVir-N-31.
• Assessment of tumor growth, viral replication, and Retinoblastoma protein levels.

Main Results:

• CDK4/6 inhibitors significantly potentiated the anti-tumor effect of XVir-N-31 in both cancer models.
• Combination therapy increased virus-producing cancer cells, viral genome replication, and particle formation.
• A decrease in Retinoblastoma protein expression was observed in response to CDK4/6 inhibitors.

Conclusions:

• CDK4/6 inhibitors enhance the oncolytic potency of adenoviruses by reducing Retinoblastoma protein levels.
• This combination strategy represents a promising approach for cancer therapy, particularly in bladder cancer and Ewing sarcoma.
• The findings provide a molecular basis for the synergistic interaction between cell cycle inhibitors and oncolytic viruses.